320 E. Vine Drive
VetDC (www.vetdc.com) is changing the way new cancer medicines are developed for companion animals, leveraging novel advancements from human biotechnology that have demonstrated success in animal studies. VetDC currently has two cancer programs in development, Tanovea for lymphoma and VDC-597 for multiple cancers.
Founder and CSO: Terry Opgenorth
CEO: Steven Roy
Please click here for clinical trial information.